NewsRoom Articles - Page 19 of 229

TuesdayAug 26, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline

CEO reports confidence about late-stage rare disease pipeline and upcoming key development milestones. Soligenix’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics and public health solutions business segments. The company's pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas. With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to…

MondayAug 25, 2025 1:15 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

Lantern Pharma completed enrollment in its LP-184 Phase 1a trial and is preparing Phase 1b/2 studies in cancers with large market potential. Early patient responses across LP-184, LP-284, and LP-300 trials highlight clinical activity in difficult-to-treat cancers. Intellectual property expanded with new European patent allowance for LP-284 and publication of blood-brain barrier prediction patent. Enhancements to RADR(R), the company’s AI platform, include public launch of predictBBB.ai(TM) and a new drug combination module. Lantern ended Q2 with $15.9 million in cash and expects its runway to extend into mid-2026. R&D expenses declined year-over-year, reflecting disciplined cost control while advancing multiple trials.…

FridayAug 22, 2025 12:00 pm

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from ketamine products. The preservative has known toxicity and is no longer allowed in hand sanitizers or topical antiseptics. Ketamine is increasingly used off-label for treating suicidal depression and PTSD. The company argues repeated exposure to benzethonium chloride through IV use poses unnecessary health risks. NRx has submitted data showing its preservative-free ketamine maintains sterility and stability for three years. The company is pursuing FDA approval for both its preservative-free ketamine (“NRX-100”) and oral NMDA-targeting drug (“NRX-101”). NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has…

FridayAug 22, 2025 10:00 am

Pioneering Therapy Could Slow the Effects of Aging

A new groundbreaking therapy could slow down or even reverse aging by recharging body cells with new “batteries” that provide new energy for bodily function. The new therapy utilizes mitochondria from the placenta of infants, which are then transplanted into older people or those suffering from diseases that are currently regarded as incurable. Minovia Therapeutics, a company based in Israel, is the first firm globally to test mitochondria transplantation in human beings as a way to help people remain younger for a longer time and also treat conditions that are regarded as incurable. Mitochondria are tiny organelles within cells, and…

ThursdayAug 21, 2025 12:45 pm

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

Clene Inc. plans to submit a New Drug Application (“NDA”) for lead candidate CNM-Au8® in ALS by year-end 2025. FDA meetings scheduled in Q3 2025 will address ALS survival benefit data and MS development plans. Neurofilament light biomarker data analysis from the NIH-sponsored EAP program is expected in early Q4 2025. The company reported $7.3 million in cash and cash equivalents as of June 30, 2025, together with recent financing extending the company’s cash runway into Q1 2026. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and…

ThursdayAug 21, 2025 10:00 am

Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors

Scientists at Columbia University have engineered a cancer treatment that leverages bacteria to smuggle cancer-killing viruses into tumors in a method that sidesteps the defenses of the immune system. This groundbreaking approach utilizes two vital weapons against the cancer; the bacteria are drawn to cancer cells, and the viruses inside the bacteria deliver the killer blow to the tumor cells after being delivered there by the bacteria. The study team was successful in creating built-in safeguards intended to prevent the viruses from infiltrating and infecting tissues outside the tumor environment. Their research promises to introduce a new paradigm in the…

WednesdayAug 20, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity

FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband's proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic…

TuesdayAug 19, 2025 10:00 am

Young Americans Face Health Insurance Chaos as They Turn 26

As young Americans turn 26, they are faced with a major transition that requires them to find their own health insurance since they no longer qualify to remain on the health insurance plan of their family. As many have found out at this transition point, getting your own insurance is a maze with many twists and turns that can leave one baffled and helpless. How did this transition come about? Back in 2010, the Affordable Care Act was passed and signed into law. This law guaranteed that young people would be assured of having health insurance until they reached the…

TuesdayAug 19, 2025 9:45 am

Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool

Lantern Pharma has publicly launched predictBBB.ai (TM), its AI-driven module for predicting small-molecule blood-brain barrier permeability. The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning. Powered by Lantern’s vast molecular features data lake and ensemble algorithms, the platform sets a new computational benchmark for CNS drug discovery. Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach. The tool is publicly accessible through a freemium model, aiming to drive adoption, strategic partnerships, and accelerate CNS therapeutic development. Lantern Pharma subsidiary Starlight Therapeutics secures FDA IND clearance…

TuesdayAug 19, 2025 9:45 am

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market

IzoView Breast CT targets aggressive market displacement with up to 67% lower pricing than competing breast CT systems, positioning at $500K versus competitors priced up to $1.5 million True 360-degree 3D imaging without compression positioned to bridge the clinical gap between standard screening and MRI, offering 100x greater spatial resolution than MRI at significantly lower cost Platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades, creating scalable revenue expansion without hardware replacement Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

Pioneering Therapy Could Slow the Effects of Aging

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors

Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity

Young Americans Face Health Insurance Chaos as They Turn 26

Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search